Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 29, 2025
Data Byte
EMA’s CHMP snubs donanemab, even for APOE4 non-carriers
Lilly to seek re-examination. Also in March meeting, CHMP backs label expansions for Opdivo, Tevimbra and more
BioCentury | Mar 19, 2025
Management Tracks
CFO Brian Stephenson exits Bridgebio
Plus: CEO Edward Kayne steps down at Stoke, and updates from Collegium, Pyxis, Recursion and Tonix
BioCentury | Mar 1, 2025
Data Byte
EMA’s CHMP reaffirms its decision to back Leqembi for Alzheimer’s
Regeneron’s bispecific, Krystal’s gene therapy, and 16 label extensions also among positive opinions issued at committee’s February meeting
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Feb 1, 2025
Data Byte
Safety of Alzheimer’s therapy again under scrutiny at EMA’s CHMP
Plus: Pfizer’s Tivdak gets CHMP nod, as Daiichi’s Dato-Dxd receives positive opinion in one indication, gets withdrawn in another
BioCentury | Jan 24, 2025
Finance
Ascentage lists on NASDAQ as Odyssey, Sionna, Aardvark plot IPOs
In BioCentury’s Finance Report, two more companies plan Hong Kong listings; Disc Medicine, Arctic raise cash
BioCentury | Jan 14, 2025
Deals
JPM ushers in flurry of biotech deals, headlined by J&J’s Intra-cellular buy
BioCentury’s Deals Report surveys deals by GSK, Idrx, Lilly, Scorpion, Lantheus, Telix, Gilead, Leo, CBC Group and more
BioCentury | Jan 8, 2025
Data Byte
Seven PDUFA dates on FDA’s January agenda
Decisions include Ozempic for CKD, a non-opioid painkiller, AZ-Daiichi’s TROP2 ADC, and an allogeneic T cell therapy
BioCentury | Dec 31, 2024
Product Development
Best of BioCentury 2024
A selection of the best stories of the year by BioCentury’s analysts
BioCentury | Dec 30, 2024
Product Development
The uncertainty principle: Hello, 2025
BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025
Items per page:
1 - 10 of 2237